TRACRIUM™
Atracurium Besylate

QUALITATIVE AND QUANTITATIVE COMPOSITION

Injection:
A sterile solution containing 10 mg atracurium besylate per ml, without an antimicrobial preservative, supplied in ampoules.

Multi-dose vial:
Injection containing atracurium besylate 10 mg per ml with 0.9% w/v benzyl alcohol as an antimicrobial preservative, supplied in vials.

PHARMACEUTICAL FORM
Solution for injection or infusion.

CLINICAL PARTICULARS

Indications
TRACRIUM is a highly selective, competitive or non-depolarising neuromuscular blocking agent which is used as an adjunct to general anaesthesia to enable tracheal intubation to be performed and to relax skeletal muscles during surgery or controlled ventilation during a wide range of medical procedures.

The multi-dose vial contains benzyl alcohol 0.9% w/v as an antimicrobial preservative and is intended for multiple use in one or more patients.

Dosage and Administration
In common with all neuromuscular blocking agents monitoring of neuromuscular function is recommended during the use of TRACRIUM in order to individualise dosage requirements.

- Use by injection in adults
TRACRIUM is administered by intravenous (i.v.) injection. The dosage range for adults is
0.3 to 0.6 mg/kg (depending on the duration of full block required) and will provide adequate relaxation for 15 to 35 minutes.

Endotracheal intubation can usually be accomplished within 90 seconds from the i.v. injection of 0.5 to 0.6 mg/kg.

Full block can be prolonged with supplementary doses of 0.1 to 0.2 mg/kg as required. Successive supplementary dosing does not give rise to accumulation of neuromuscular blocking effect.

Spontaneous recovery from the end of full block occurs in about 35 minutes as measured by the restoration of the tetanic response to 95% of normal neuromuscular function.
The neuromuscular block produced by TRACRIUM can be rapidly reversed by standard doses of anticholinesterase agents, such as neostigmine and edrophonium, accompanied or preceded by atropine, with no evidence of recurarisation.

- **Use as an infusion in adults**

After an initial bolus dose of 0.3 to 0.6 mg/kg, TRACRIUM can be used to maintain neuromuscular block during long surgical procedures by administration as a continuous infusion at rates of 0.3 to 0.6 mg/kg/h.

TRACRIUM can be administered by infusion during cardiopulmonary bypass surgery at the recommended infusion rates. Induced hypothermia to a body temperature of 25°C to 26°C reduces the rate of inactivation of TRACRIUM, therefore full neuromuscular block may be maintained by approximately half the original infusion rate at these low temperatures.

TRACRIUM (multi-dose vials and injection) is compatible with the following infusion solutions for the times stated below:

<table>
<thead>
<tr>
<th>Infusion Solution</th>
<th>Period of Stability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium Chloride i.v. Infusion British Pharmacopoeia (BP) (0.9% w/v)</td>
<td>24 hours</td>
</tr>
<tr>
<td>Glucose i.v. Infusion BP (5% w/v)</td>
<td>8 hours</td>
</tr>
<tr>
<td>Ringer's Injection United States Pharmacopoeia (USP)</td>
<td>8 hours</td>
</tr>
<tr>
<td>Sodium Chloride (0.18% w/v) and Glucose (4% w/v) i.v. Infusion BP</td>
<td>8 hours</td>
</tr>
<tr>
<td>Compound Sodium Lactate i.v. Infusion BP (Hartmann’s Solution for Injection)</td>
<td>4 hours</td>
</tr>
</tbody>
</table>

When diluted in these solutions to give TRACRIUM concentrations of 0.5 mg/ml and above, the resultant solutions will be stable in daylight for the stated periods at temperatures of up to 30°C.

- **Use in children**

The dosage in children over the age of 1 month is the same as that in adults on a bodyweight basis.

- **Use in the elderly**

TRACRIUM may be used at standard dosage in elderly patients. It is recommended, however, that the initial dose be at the lower end of the range and that it be administered slowly.

- **Use in patients with reduced renal and/or hepatic function**
TRACRIUM may be used at standard dosage at all levels of renal or hepatic function, including end-stage failure.

- **Use in patients with cardiovascular disease**

In patients with clinically significant cardiovascular disease, the initial dose of TRACRIUM should be administered over a period of 60 seconds.

**Contraindications**

*Injection:*

- TRACRIUM is contraindicated in patients known to be hypersensitive to atracurium, cisatracurium or benzenesulfonic acid.

*Multi-dose vial:*

- TRACRIUM (multi-dose vial) is contraindicated in patients known to be hypersensitive to atracurium, cisatracurium, benzenesulfonic acid or benzyl alcohol.

**Warnings and Precautions**

In common with all the other neuromuscular blocking agents TRACRIUM paralyses the respiratory muscles as well as other skeletal muscles but has no effect on consciousness. TRACRIUM should be administered only with adequate general anaesthesia and only by or under the close supervision of an experienced anaesthetist with adequate facilities for endotracheal intubation and artificial ventilation.

The potential for histamine release exists in susceptible patients during TRACRIUM administration. Caution should be exercised in administering TRACRIUM to patients with a history suggestive of an increased sensitivity to the effects of histamine.

Caution should also be exercised when administering TRACRIUM to patients who have shown hypersensitivity to other neuromuscular blocking agents since a high rate of cross-sensitivity (greater than 50%) between neuromuscular blocking agents has been reported (see Contraindications).

TRACRIUM does not have significant vagal or ganglionic blocking properties in the recommended dosage range. Consequently, TRACRIUM has no clinically significant effects on heart rate in the recommended dosage range and it will not counteract the bradycardia produced by many anaesthetic agents or by vagal stimulation during surgery.

In common with other non-depolarising neuromuscular blocking agents, increased sensitivity to TRACRIUM may be expected in patients with myasthenia gravis, other forms of neuromuscular disease and severe electrolyte imbalance.

TRACRIUM should be administered over a period of 60 seconds to patients who may be unusually sensitive to falls in arterial blood pressure, for example those who are hypovolaemic.

TRACRIUM is inactivated by high pH and so must not be mixed in the same syringe with thiopentone or any alkaline agent.
When a small vein is selected as the injection site, TRACRIUM should be flushed through the vein with physiological saline after injection. When other anaesthetic drugs are administered through the same in-dwelling needle or cannula as TRACRIUM it is important that each drug is flushed through with an adequate volume of physiological saline.

TRACRIUM is hypotonic and must not be administered into the infusion line of a blood transfusion.

Studies in malignant hyperthermia in susceptible animals (swine) and clinical studies in patients susceptible to malignant hyperthermia indicate that TRACRIUM does not trigger this syndrome.

In common with other non-depolarising neuromuscular blocking agents, resistance may develop in patients suffering from burns. Such patients may require increased doses dependent on the time elapsed since the burn injury and the extent of the burn.

Injection:

Intensive Care Unit (ICU) Patients: When administered to laboratory animals in high doses, laudanosine, a metabolite of atracurium, has been associated with transient hypotension and in some species, cerebral excitatory effects. Although seizures have been seen in ICU patients receiving TRACRIUM, a causal relationship to laudanosine has not been established (see Adverse Reactions).

Multi-dose vial:

Benzyl alcohol is used as an antimicrobial preservative in many parenteral drug formulations, including TRACRIUM multi-dose vial. Due to reports linking the use of parenteral drug formulations containing benzyl alcohol to morbidity and mortality amongst low weight neonates such formulations should be used with caution in neonates and theoretically, in other patient groups suspected of possessing a reduced ability to metabolise benzyl alcohol.

Interactions

The neuromuscular block produced by TRACRIUM may be increased by the concomitant use of inhalational anaesthetics such as halothane, isoflurane and enflurane.

In common with all non-depolarising neuromuscular blocking agents the magnitude and/or duration of a non-depolarising neuromuscular block may be increased as a result of interaction with:

- antibiotics: including the aminoglycosides, polymyxins, spectinomycin, tetracyclines, lincomycin and clindamycin
- antiarrhythmic drugs: propranolol, calcium channel blockers, lidocaine, procainamide and quinidine
- diuretics: furosemide and possibly mannitol, thiazide diuretics and acetazolamide
- magnesium sulphate
- ketamine
- lithium salts
- ganglion blocking agents: trimetaphan, hexamethonium.

Rarely, certain drugs may aggravate or unmask latent myasthenia gravis or actually induce a myasthenic syndrome; increased sensitivity to TRACRIUM would be consequent on such a development. Such drugs include various antibiotics, beta-blockers (propranolol, oxprenolol), antiarrhythmic drugs (procainamide, quinidine), anti-rheumatic drugs (chloroquine, D-penicillamine), trimetaphan, chlorpromazine, steroids, phenytoin and lithium.

The onset of non-depolarising neuromuscular block is likely to be lengthened and the duration of block shortened in patients receiving chronic anticonvulsant therapy.

The administration of combinations of non-depolarising neuromuscular blocking agents in conjunction with TRACRIUM may produce a degree of neuromuscular blockade in excess of that which might be expected were an equipotent total dose of TRACRIUM administered. Any synergistic effect may vary between different drug combinations.

A depolarising muscle relaxant such as suxamethonium chloride should not be administered to prolong the neuromuscular blocking effects of non-depolarising agents such as TRACRIUM, as this may result in a prolonged and complex block which can be difficult to reverse with anti-cholinesterase drugs.

Treatment with anticholinesterases, commonly used in the treatment of Alzheimer's disease e.g. donepezil, may shorten the duration and diminish the magnitude of neuromuscular blockade with atracurium.

Pregnancy and Lactation

Fertility
Fertility studies have not been performed.

Pregnancy
Use in Pregnancy: Atracurium has been shown to cross the placenta to a limited degree although the transfer of metabolites may be greater. Animal studies of teratogenic potential are limited to a single study in which pregnant rabbits received subcutaneous doses of 0.15 mg/kg once daily or 0.1 mg/kg twice daily during the period of organogenesis. There was no clear evidence of teratogenic activity at these doses, which are less than those used clinically, although there was some indication of fetotoxicity manifest as slight increases in the incidences of minor skeletal and visceral anomalies. There are no adequate and well controlled studies in pregnant women. In common with all neuromuscular blocking agents, TRACRIUM should be used in pregnant women only if in the opinion of the physician, the potential benefit outweighs any potential risk to the foetus.

Obstetrics
In an open study, TRACRIUM was administered (0.3 mg/kg) to 26 pregnant women during delivery by Caesarean section. No harmful effects were attributable to TRACRIUM in any of the newborn infants, although TRACRIUM was shown to cross the placental barrier. The possibility of respiratory depression in the newborn infant should always be considered following Caesarean section during which a
neuromuscular blocking agent has been administered. In Patients receiving magnesium sulphate, the reversal of neuromuscular blockade may be unsatisfactory and TRACRIUM dose should be lowered as indicated.

In common with all neuromuscular blocking agents, TRACRIUM should be used during pregnancy only if the potential benefit to the mother outweighs any potential risk to the foetus.

TRACRIUM is suitable for maintenance of muscle relaxation during Caesarean section as it does not cross the placenta in clinically significant amounts following recommended doses.

**Lactation**

It is not known whether atracurium is excreted in human milk.

**Effects on Ability to Drive and Use Machines**

This precaution is not relevant to the use of TRACRIUM. TRACRIUM will always be used in combination with a general anaesthetic and therefore the usual precautions relating to performance of tasks following anaesthesia apply.

**Adverse Reactions**

Adverse reactions are listed below by system organ class and frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100 to < 1/10), uncommon (≥1/1000 to < 1/100), rare (≥1/10,000 to < 1/1000), very rare (< 1/10,000). Very common, common and uncommon frequencies were determined from clinical trial data. Rare and very rare frequencies were generally derived from spontaneous data. The frequency classification "Not known" has been applied to those reactions where a frequency could not be estimated from the available data.

**Clinical Trial Data**

**Vascular Disorders**

Events which have been attributed to histamine release are indicated by a hash (#).

Common: Hypotension (mild, transient)#, Skin flushing#

**Respiratory, thoracic and mediastinal disorders**

Events which have been attributed to histamine release are indicated by a hash (#).

Uncommon: Bronchospasm#

**Post-Marketing Data**

**Immune system disorders**

Very rare: Anaphylactic reaction, anaphylactoid reaction

Very rarely, severe anaphylactoid or anaphylactic reactions have been reported in patients receiving TRACRIUM in conjunction with one or more anaesthetic agents.
Nervous system disorder
Not known: Seizures
There have been reports of seizures in ICU patients who have been receiving atracurium concurrently with several other agents. These patients usually had one or more medical conditions predisposing to seizures (e.g. cranial trauma, cerebral oedema, viral encephalitis, hypoxic encephalopathy, uraemia). A causal relationship to laudanosine has not been established. In clinical trials, there appears to be no correlation between plasma laudanosine concentration and the occurrence of seizures.

Skin and subcutaneous tissue disorders
Rare: Urticaria

Musculoskeletal and connective tissue disorders
Not known: Myopathy, muscle weakness
There have been some reports of muscle weakness and/or myopathy following prolonged use of muscle relaxants in severely ill patients in the ICU. Most patients were receiving concomitant corticosteroids. These events have been seen infrequently in association with atracurium and a causal relationship has not been established.

Overdose
Symptoms and Signs
Prolonged muscle paralysis and its consequences are the main signs of overdosage.

Treatment
It is essential to maintain a patent airway together with assisted positive pressure ventilation until spontaneous respiration is adequate.

Full sedation will be required since consciousness is not impaired.

Recovery may be hastened by the administration of anticholinesterase agents accompanied by atropine or glycopyrrolate, once evidence of spontaneous recovery is present.

PHARMACOLOGICAL PROPERTIES
Pharmacodynamics
Mechanism of Action
Atracurium is a highly selective, competitive or non-depolarising neuromuscular blocking agent.

Pharmacodynamic Effects
TRACRIUM has no direct effect on intra-ocular pressure, and is therefore suitable for use in ophthalmic surgery.

Pharmacokinetics
Metabolism
Atracurium is inactivated by Hofmann elimination, a non-enzymatic process which occurs at physiological pH and temperature, and by ester hydrolysis catalysed by non-specific esterases.
Tests with plasma from patients with low levels of pseudocholinesterase show that the inactivation of atracurium proceeds unaffected.
Variations in the blood pH and body temperature of the patient within the physiological range will not significantly alter the duration of action of atracurium.

Elimination
The termination of the neuromuscular blocking action of TRACRIUM is not dependent on its hepatic or renal metabolism or excretion. Its duration of action, therefore, is unlikely to be affected by impaired renal, hepatic or circulatory function.
The elimination half-life of atracurium is approximately 20 minutes, and the volume of distribution is 0.16 L/kg. Atracurium is 82% bound to plasma proteins

Special Patient Populations
Injection:
Haemofiltration and haemodiafiltration have a minimal effect on plasma levels of atracurium and its metabolites, including laudanosine. The effects of haemodialysis and haemoperfusion on plasma levels of atracurium and its metabolites are unknown.
Concentrations of metabolites are higher in ICU patients with abnormal renal and/or hepatic function (see Warnings and Precautions). These metabolites do not contribute to neuromuscular block.

Pre-clinical Safety Data
Mutagenicity:
Atracurium has been evaluated in three short-term mutagenicity tests. It was not mutagenic in either the in vitro Ames salmonella assay at concentrations up to 1000 micrograms/plate or in an in vivo rat bone marrow assay at doses up to those which resulted in neuromuscular blockade. In a second in vitro test, the mouse lymphoma assay, mutagenicity was not observed at doses up to 60 micrograms/ml which killed up to 50% of the treated cells but it was moderately mutagenic at concentrations of 80 micrograms/ml in the absence of metabolising agent and weakly mutagenic at very high concentrations (1200 micrograms/ml) when metabolising enzymes were added. At both concentrations over 80% of the cells were killed.
In view of the nature of human exposure to TRACRIUM, the mutagenic risk to patients undergoing surgical relaxation with TRACRIUM must be considered negligible.

Carcinogenicity:
Carcinogenicity studies have not been performed.
LONG-TERM USE IN THE INTENSIVE CARE UNIT (ICU)

*TRACRIUM* has been used to facilitate mechanical ventilation in ICU patients. When there is a need for long-term mechanical ventilation, the risk-benefit ratio of neuromuscular blockade must be considered.

For *TRACRIUM*, as with other neuromuscular blocking agents used in intensive care units, available evidence suggests that there is wide interpatient variability in dosage requirements and that requirements may change with time. Limited data suggest that *TRACRIUM* infusion requirements may increase with prolonged administration in the ICU. The effects of haemodialysis, haemoperfusion and haemofiltration on plasma levels of atracurium and its metabolites are unknown.

One metabolite of atracurium, laudanosine, when administered alone to laboratory animals, has been associated with cerebral excitatory effects. No pharmacological effects of laudanosine have been demonstrated in humans even after days/weeks of prolonged infusion.

PHARMACEUTICAL PARTICULARS

**List of Excipients**

Multi-dose vial contains benzyl alcohol.

**Special Precautions for Storage**

Short periods at temperatures up to 25°C are permissible but ONLY to allow transportation or temporary storage outside of a cold store. It is estimated that a 5% loss of potency would occur if *TRACRIUM* injection was stored at 25°C for one month.

Store at temperatures between 2°C and 8°C.

Protect from light.

Do not freeze.

Any unused *TRACRIUM* injection from opened ampoules should be discarded.

**Instructions for Use/Handling**

*TRACRIUM* is compatible with the following infusion solutions for the times stated below.

<table>
<thead>
<tr>
<th>Infusion Solution</th>
<th>Period of Stability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium Chloride i.v. Infusion BP (0.9% w/v)</td>
<td>24 hours</td>
</tr>
<tr>
<td>Glucose i.v. Infusion BP (5% w/v)</td>
<td>8 hours</td>
</tr>
<tr>
<td>Ringer’s Injection USP</td>
<td>8 hours</td>
</tr>
<tr>
<td>Sodium Chloride (0.18% w/v) and Glucose (4% w/v) i.v. Infusion BP</td>
<td>8 hours</td>
</tr>
</tbody>
</table>
Compound Sodium Lactate i.v. Infusion BP (Hartmann’s Solution for Injection) 4 hours

When diluted in these solutions to give TRACRIUM concentrations of 0.5 mg/ml and above, the resultant solutions will be stable in daylight for the stated periods at temperatures of up to 30°C.

TRACRIUM multi-dose vial contains 0.9% w/v benzyl alcohol as an antimicrobial preservative and is intended for multiple use in one or more patients. It is good clinical practice to discard any partly used vials at the end of an operating day.

Not all presentations are available in every country.

Version number: GDS19/IPI06SI

Date of issue: 03 June 2013

Manufactured by: GlaxoSmithKline Manufacturing S.p.A., Parma, Italy.

TRACRIUM is a trademark of the GlaxoSmithKline group of companies [GlaxoSmithKline logo]